OS Therapies (NYSEAMERICAN:OSTX) Given New $13.00 Price Target at Lake Street Capital

OS Therapies (NYSEAMERICAN:OSTX) had its target price decreased by equities researchers at Lake Street Capital from $14.00 to $13.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Other research analysts have also recently issued research reports about the stock. D. Boral Capital restated a “buy” rating and set a $20.00 price objective on shares of OS Therapies in a report on Thursday, April 30th. Zacks Research cut shares of OS Therapies from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $16.50.

OS Therapies Stock Performance

NYSEAMERICAN:OSTX traded down $0.02 during mid-day trading on Tuesday, hitting $1.71. The company had a trading volume of 118,334 shares, compared to its average volume of 646,834. OS Therapies has a fifty-two week low of $1.15 and a fifty-two week high of $2.57. The firm has a market cap of $67.60 million, a P/E ratio of -1.72 and a beta of -1.34. The business’s fifty day moving average is $1.52 and its two-hundred day moving average is $1.55.

OS Therapies (NYSEAMERICAN:OSTX) last announced its quarterly earnings results on Monday, May 18th. The company reported ($0.27) EPS for the quarter. Equities analysts forecast that OS Therapies will post 0.16 earnings per share for the current year.

Institutional Trading of OS Therapies

Several hedge funds have recently bought and sold shares of the stock. Mercer Global Advisors Inc. ADV bought a new position in OS Therapies in the third quarter valued at approximately $40,000. Ground Swell Capital LLC acquired a new stake in shares of OS Therapies during the third quarter worth $40,000. Geode Capital Management LLC raised its holdings in shares of OS Therapies by 31.1% during the fourth quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock worth $344,000 after acquiring an additional 58,350 shares during the period. Millennium Management LLC bought a new stake in OS Therapies in the 3rd quarter valued at $183,000. Finally, Two Sigma Investments LP bought a new stake in OS Therapies in the 3rd quarter valued at $169,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.